Literature DB >> 2031965

Correction of neutropenia associated with chronic lymphocytic leukaemia following treatment with granulocyte-macrophage colony-stimulating factor.

A A Hollander1, H C Kluin-Nelemans, H R Haak, A C Stern, R Willemze, W E Fibbe.   

Abstract

A patient with chronic lymphocytic leukaemia (CLL) and severe persisting neutropenia due to marrow infiltration of his leukaemia, developed bilateral Legionella pneumophila pneumonia for which he was treated with erythromycin, rifampin and ciprofloxacin. To increase the number of circulating polymorphonuclear neutrophils, the patient was treated with recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) at a dose of 2 micrograms protein/kg bodyweight s.c./12 h. GM-CSF therapy resulted in a sustained rise of the neutrophil count from the fifth day of treatment onwards, without showing an effect on the number of circulating leukemic cells. The patient completely recovered from his pneumonia. It is suggested that the rise of the neutrophil count, due to GM-CSF, contributed to the improvement of the infection of this patient. Our observation illustrates that GM-CSF can be given safely to CLL-patients and that it can be used effectively in CLL patients with severe bacterial infections to restore neutropenia.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2031965     DOI: 10.1007/bf01714981

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  8 in total

1.  Mechanisms of infection in chronic lymphocytic leukemia.

Authors:  H M Chapel; C Bunch
Journal:  Semin Hematol       Date:  1987-10       Impact factor: 3.851

Review 2.  Biological activities of human granulocyte-macrophage colony-stimulating factor.

Authors:  S C Clark
Journal:  Int J Cell Cloning       Date:  1988-11

3.  Use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous marrow transplantation for lymphoid malignancies.

Authors:  J Nemunaitis; J W Singer; C D Buckner; R Hill; R Storb; E D Thomas; F R Appelbaum
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

Review 4.  The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors.

Authors:  D Metcalf
Journal:  Blood       Date:  1986-02       Impact factor: 22.113

5.  Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.

Authors:  S Vadhan-Raj; M Keating; A LeMaistre; W N Hittelman; K McCredie; J M Trujillo; H E Broxmeyer; C Henney; J U Gutterman
Journal:  N Engl J Med       Date:  1987-12-17       Impact factor: 91.245

6.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome.

Authors:  J E Groopman; R T Mitsuyasu; M J DeLeo; D H Oette; D W Golde
Journal:  N Engl J Med       Date:  1987-09-03       Impact factor: 91.245

7.  Granulocyte-macrophage colony-stimulating factor enhances phagocytosis of bacteria by human neutrophils.

Authors:  J Fleischmann; D W Golde; R H Weisbart; J C Gasson
Journal:  Blood       Date:  1986-09       Impact factor: 22.113

8.  Biosynthetic (recombinant) human granulocyte-macrophage colony-stimulating factor: effect on normal bone marrow and leukemia cell lines.

Authors:  M Tomonaga; D W Golde; J C Gasson
Journal:  Blood       Date:  1986-01       Impact factor: 22.113

  8 in total
  3 in total

1.  Successful short-term treatment with granulocyte-macrophage colony-stimulating factor of neutropenia due to cytotoxic chemotherapy of chronic lymphocytic leukemia.

Authors:  K Rave; G Brittinger
Journal:  Ann Hematol       Date:  1991-12       Impact factor: 3.673

2.  Recombinant Granulocyte-Macrophage Colony-Stimulating Factor (rGM-CSF) : A Review of its Pharmacological Properties and Prospective Role in the Management of Myelosuppression.

Authors:  Susan M Grant; Rennie C Heel
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

Review 3.  Current approaches to the treatment and management of chronic lymphocytic leukaemia.

Authors:  E Montserrat; C Rozman
Journal:  Drugs       Date:  1994       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.